SCHEMBL26125533

SCHEMBL26125533

c1ccc2cc(-c3cc(-c4cnc(-c5ccc(-c6cc7ccccc7c7ccccc67)cc5)nc4)cc(-c4ccc5ccccc5c4)c3)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 2/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ NFKB1 P19838 2/20 0.40
▸ NFKB2 Q00653 2/20 0.40
▸ RELA Q04206 2/20 0.40
▸ CYP17A1 P05093 1/20 0.40
▸ CYP19A1 P11511 1/20 0.40
▸ CYP11B2 P19099 1/20 0.40
▸ DHFR P00374 1/20 0.39
▸ MAPK9 P45984 2/20 0.39
▸ MAPK10 P53779 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ SGK1 O00141 3/20 0.37
▸ GPR84 Q9NQS5 1/20 0.37
▸ MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29831538 1.00 CYP11B1 (0.44) CYP11B1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL29831682 0.90 NPC1 (0.45) CYP11B1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL26124152 0.90 NPC1 (0.45) CYP11B1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL24910261 0.88 NPC1 (0.52) CYP11B1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL29832043 0.88 NPC1 (0.52) CYP11B1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL29832722 0.87 PDGFRB (0.48) CYP11B1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL26122111 0.87 PDGFRB (0.48) CYP11B1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL29831543 0.84 CYP11B1 (0.43) CYP11B1NPC1RAB9ACYP17A1CYP19A1
SCHEMBL24686227 0.83 CYP11B1 (0.46) CYP11B1SMN1; SMN2MAPTCYP17A1CYP19A1
SCHEMBL17932440 0.82 CYP11B1 (0.41) CYP11B1SMN1; SMN2NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240049595-A1 HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS HODOGAYA CHEMICAL CO., LTD. (JP) 2024-02-08 — — US disclosed
EP-4257585-A1 HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE Hodogaya Chemical Co., Ltd. (JP) 2023-10-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240049595-A1 HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS LAGE3, EED, EZH1 CYP11B1 4152/4885SMN1; SMN2 3855/4885NPC1 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback